Bantam Pharmaceutical, a drug discovery and development company targeting selective modulation of mitochondrial dynamics in ...
Currently More Than 400 Clinical Trials Studies Are Active In Saudi Arabia Says Kuick Research In New Research ReportDelhi, ...
Clinical trial complexity has significantly increased in the past decade. How can the industry adapt and innovate to remain ...
Trial decision follows unanticipated events of elevated unconjugated bilirubin levelsCompany advancing multiple next-generation PTH1R agonists ...
If this CEO succeeds N-Power could save millions of dollars and lives in the fight against cancer. "The impact for cancer ...
NEWARK, CA / ACCESS Newswire / February 21, 2025 / Protagonist Therapeutics (NASDAQ:PTGX) ("Protagonist" or "the Company") today reported financial results for the fourth quarter and full year ended ...
Altimmune's existence depends almost entirely on the outcome of the Phase 2 trial for pemvidutide in MASH. Learn why ALT ...
The field of central nervous system (CNS) drug development is awash with activity. And major new centres of research are ...
Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (“Satellos” or the “Company”), a public biotech company developing new ...
Sarah Hubar-Fisher will be Yaqrit's VP of Business Development with particular responsibility for the two medical device assets entering registrational trials in 2025. Her 20 years at Johnson & ...
Protagonist Therapeutics, Inc. (NASDAQ:PTGX), a biopharmaceutical company with a market capitalization of $2.3 billion focused on developing peptide-based drugs, stands at a pivotal juncture in its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback